GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » Profitability Rank

PHAXIAM Therapeutics (XPAR:PHXM) Profitability Rank : 1 (As of Sep. 2023)


View and export this data going back to 2013. Start your Free Trial

What is PHAXIAM Therapeutics Profitability Rank?

PHAXIAM Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

PHAXIAM Therapeutics's Operating Margin % for the quarter that ended in Sep. 2023 was %. As of today, PHAXIAM Therapeutics's Piotroski F-Score is 3.


Competitive Comparison of PHAXIAM Therapeutics's Profitability Rank

For the Biotechnology subindustry, PHAXIAM Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PHAXIAM Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's Profitability Rank falls into.



PHAXIAM Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

PHAXIAM Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

PHAXIAM Therapeutics's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=-5.757 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

PHAXIAM Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


PHAXIAM Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


PHAXIAM Therapeutics (XPAR:PHXM) Business Description

Traded in Other Exchanges
Address
60 Avenue Rockefeller, Lyon, FRA, 69008
Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.

PHAXIAM Therapeutics (XPAR:PHXM) Headlines